Literature DB >> 8321850

A new route of drug administration: intrauterine delivery of insulin and calcitonin.

G Golomb1, A Avramoff, A Hoffman.   

Abstract

High molecular weight drugs in general, and peptides in particular, are usually delivered by parenteral route because they are poorly absorbed or degraded in the gastrointestinal tract. To optimize therapy, it is desirable to search for nonparenteral routes of administration and to deliver the drug in a controlled-release fashion. We report here on the absorption and the systemic biological effect of two peptides, insulin and calcitonin, after instillation into the uterus of the rat. Intrauterine delivery was compared to subcutaneous injections in intact and ovariectomized rats. In addition, we describe results of a preliminary study on calcitonin absorption from controlled-release matrices inserted in the rat uterus. The amount and duration of the hypoglycemic and the hypocalcemic effects induced by intrauterine delivery of insulin and calcitonin, respectively, were equivalent to those obtained after subcutaneous injections. The results were similar in intact and ovariectomized rats. It is concluded that the intrauterine administration of both insulin and calcitonin is bioequivalent to subcutaneous injection. The therapy of a number of clinically important diseases could benefit from this discovery.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8321850     DOI: 10.1023/a:1018948924992

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

1.  International Standards for salmon calcitonin, eel calcitonin, and the Asu1-7 analogue of eel calcitonin: calibration by international collaborative study.

Authors:  J M Zanelli; R E Gaines-Das; P H Corran
Journal:  Bone Miner       Date:  1990-10

2.  Prevention of bacterial colonization on polyurethane in vitro by incorporated antibacterial agent.

Authors:  G Golomb; A Shpigelman
Journal:  J Biomed Mater Res       Date:  1991-08

3.  Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo.

Authors:  G Golomb; A Schlossman; H Saadeh; M Levi; J M Van Gelder; E Breuer
Journal:  Pharm Res       Date:  1992-01       Impact factor: 4.200

4.  The effect of rectal and nasal administration of salmon calcitonin in normal subjects.

Authors:  T Buclin; J P Randin; A F Jacquet; M Azria; M Attinger; F Gomez; P Burckhardt
Journal:  Calcif Tissue Int       Date:  1987-11       Impact factor: 4.333

5.  LAGRAN program for area and moments in pharmacokinetic analysis.

Authors:  M L Rocci; W J Jusko
Journal:  Comput Programs Biomed       Date:  1983-06

6.  The absorption of insulin from various regions of the rat intestine.

Authors:  M Kidron; H Bar-On; E M Berry; E Ziv
Journal:  Life Sci       Date:  1982-12-20       Impact factor: 5.037

7.  Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating.

Authors:  G Golomb; M Dixon; M S Smith; F J Schoen; R J Levy
Journal:  J Pharm Sci       Date:  1987-04       Impact factor: 3.534

8.  Calcitonin as a drug.

Authors:  L J Deftos; B P First
Journal:  Ann Intern Med       Date:  1981-08       Impact factor: 25.391

9.  Prevention of bioprosthetic heart valve tissue calcification by charge modification: effects of protamine binding by formaldehyde.

Authors:  G Golomb; V Ezra
Journal:  J Biomed Mater Res       Date:  1991-01

10.  Vaginal absorption of insulin in the rat: effect of penetration enhancers on insulin uptake and mucosal histology.

Authors:  J L Richardson; L Illum; N W Thomas
Journal:  Pharm Res       Date:  1992-07       Impact factor: 4.200

  10 in total
  2 in total

1.  Temperature and pH-sensitive polymers for human calcitonin delivery.

Authors:  A Serres; M Baudys; S W Kim
Journal:  Pharm Res       Date:  1996-02       Impact factor: 4.200

Review 2.  Pharmacokinetic considerations of new insulin formulations and routes of administration.

Authors:  A Hoffman; E Ziv
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.